The Use of Cyproheptadine in Pediatric Feeding Disorders

Description

The goal of this clinical trial is to learn if Cyproheptadine, an appetite stimulant, can improve eating habits in children with Pediatric Feeding Disorders. Pediatric Feeding Disorders is a broad term that describes disorders of eating-related behaviors that causes altered consumption of food and impairs physical or psychosocial health.

Conditions

Pediatric Feeding Disorder, Chronic, Avoidant Restrictive Food Intake Disorder

Study Overview

Study Details

Study overview

The goal of this clinical trial is to learn if Cyproheptadine, an appetite stimulant, can improve eating habits in children with Pediatric Feeding Disorders. Pediatric Feeding Disorders is a broad term that describes disorders of eating-related behaviors that causes altered consumption of food and impairs physical or psychosocial health.

The Use of Cyproheptadine to Improve Eating Habits in Children With Pediatric Feeding Disorders

The Use of Cyproheptadine in Pediatric Feeding Disorders

Condition
Pediatric Feeding Disorder, Chronic
Intervention / Treatment

-

Contacts and Locations

Miami

University of Miami Department of Pediatric Gastroenterology, Miami, Florida, United States, 30345

Participation Criteria

Researchers look for people who fit a certain description, called eligibility criteria. Some examples of these criteria are a person's general health condition or prior treatments.

For general information about clinical research, read Learn About Studies.

Eligibility Criteria

  • * Any patient aged 2-6 years of age who presents to Pediatric Gastroenterology Clinic with complaint of "poor weight gain, malnutrition, failure to thrive/weight faltering, picky eating, or feeding issues" who screens positive for a pediatric feeding disorder using the Child eating disorder questionnaire (CEBQ)
  • * Age Range: 2-6 years
  • * English or Spanish speaking
  • * Patients who are tube fed
  • * Patients who are overweight (BMI at 85th%tile or greater)
  • * Patients who have active symptoms from a diagnosis of a GI disorder (Inflammatory Bowel Disease, Eosinophilic Esophagitis, Gastritis)
  • * Patients actively undergoing behavioral feeding therapy

Ages Eligible for Study

2 Years to 6 Years

Sexes Eligible for Study

ALL

Accepts Healthy Volunteers

No

Collaborators and Investigators

University of Miami,

Miguel Saps, MD, PRINCIPAL_INVESTIGATOR, University of Miami

Study Record Dates

2025-12-30